“…Accordingly, therapeutic approaches aimed at normalising low endocannabinoid levels following abstinence, when withdrawal symptoms emerge, may be essential not only to prevent relapse and treating cannabis use disorders but also perhaps to treat/avoid cannabis-induced psychotic symptoms during withdrawal in vulnerable individuals. Consistent with previous reports (Joseph et al, 2018;Marín et al, 2021;Shakya and Upadhaya, 2021;Kung et al, 2022;Ramos et al, 2022), the cases described in this article showed improvement after administration of dopamine D2 blockers. Nonetheless, alternative treatments other than targeting the dopaminergic system may be warranted.…”